Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conferenceseries Ltd: World’s leading Event Organizer

Conference Series Conferences gaining more Readers and Visitors

Conference Series Web Metrics at a Glance

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Previous Speakers

 Barbara holtz

Barbara holtz

Collaborative Drug Discovery, Inc. UK

Victor J. Hruby

Victor J. Hruby

University of Arizona USA

Carsten Detering

Carsten Detering

BioSolveIT Inc USA

Thorsten Nowak

Thorsten Nowak

C4X Discovery UK

Concepción González-Bello

Concepción González-Bello

Universidade de Santiago de Compostela Spain

Tatsuya Takagi

Tatsuya Takagi

Osaka University Japan

Marc Le Borgne

Marc Le Borgne

University Lyon 1 France

Neal Goodwin

Neal Goodwin

Champions Oncology, Inc. USA

Drug Discovery 2017

Session/Tracks

Conference Series is delighted to invite you to attend the 3rd International Conference and Expo on Drug Discovery & Designing, one of its remarkable Pharmaceutical conferences, to be held during October 02-04, 2017 in Vienna, Austria emphasizing on recent areas of more optimized research techniques like rational and computer aided drug designing for the Discovery, Designing and Development of new drugs than by traditional hit and trial method. 

Drug Discovery 2017 focuses on discussing the treatment strategies, risk management and consequences and challenges in drug design and discovery industry. Drug Discovery 2017 provides a platform to critically analyse and understand the methods and mechanisms. 

Track 1:  Drug Designing

Drug Design is an impressive inventive process of new medication on the basis of biological target. It is also known as rational drug design or rational design. That is the development in medical history in order to yield significant therapeutic response. The drug is an organic molecule, when it is predicament to target site it can either inhibit or activate the function of a biomolecule which effects in therapeutic benefit. The drug design involves the design of such molecules that are similar to the bio molecular target site in shape and charge in order to bind to it. Drug design relies on the knowledge of the three dimensional structure of bimolecular targets.

Relevant Conferences:

7th European Biosimilars Congress May 15-17, 2017  Munich, Germany; 8th World Congress on Pharmacology, August 07-09, 2017, Paris, France; 6th World Pharmacists and Clinical Pharmacy Annual Congress May 22-24, 2017 Chicago, USA; 8th Annual Pharmaceutical Analysis Congress September 25-27,2017 Vienna, Austria ; Drug Discovery and Therapy World Congress July 10-13, 2017, USA; 4th Annual Drug Discovery Congress October 2017, USA; 18th Annual Drug Discovery Summit 12-13 June 2017, Berlin, Germany; 3rd Drug Discovery Re-Invented Conference  February 21-24 2017 Cancun, Mexico.

Relevant Societies:

European Association for Chemical and Molecular Sciences| European Federation for Pharmaceutical Sciences (EUFEPS) | American Chemical Society (ACS)| Drug Watch.

Track 2: Perspective In Drug Discovery

 It is driven by chemistry but increasingly guided by pharmacology and the clinical Sciences, drug research has contributed more to the development of medicine during the past century than any other scientific factor. Improving the science of drug development and directive is important in fulfilling the public health. The advent of molecular biology and, in particular, of genomic sciences is having a deep effect on drug discovery. Emphasis is placed on the contrast between the academic and industrial research operating environments, which can influence the efficacy of research collaboration between the two communities, but which plays such an important role in drug innovation. The strategic challenges that research directors face are also emphasized.

Relevant Conferences:

7th European Biosimilars Congress May 15-17, 2017  Munich, Germany; 8th World Congress on Pharmacology, August 07-09, 2017, Paris, France; 6th World Pharmacists and Clinical Pharmacy Annual Congress May 22-24, 2017 Chicago, USA; 8th Annual Pharmaceutical Analysis Congress September 25-27,2017 Vienna, Austria ; Drug Discovery and Therapy World Congress July 10-13, 2017, USA; 4th Annual Drug Discovery Congress October 2017, USA; 18th Annual Drug Discovery Summit 12-13 June 2017, Berlin, Germany; 3rd Drug Discovery Re-Invented Conference  February 21-24 2017 Cancun, Mexico.

Relevant Societies:

Chemical Society Reviews | American Society for Pharmacology and Experimental Therapeutics (ASPET)| American Society for Biochemistry and Molecular Biology (ASBMB).

Track 3: Computer Aided Drug Design (CADD)

Drug Design through computer, a latest, very effective technique in modern arena. Now a days Computer Aided Drug Design (CADD) tools are cast-off in nanotechnology, molecular biology, biochemistry etc. The main benefit of the CADD is total effective in research and development of drugs. There are wide ranges of software are used in CADD, Grid computing, window created general PBPK/PD  modelling software, PKUDDS for structure based drug design,APIS, JAVA, Perl and Python, CADD as well as software including software libraries. There are different techniques used in CADD visualization, homology, molecular vibrant, energy minimization molecular docking, QSAR etc. Drug design conference-2016 provides a stage to critically analyse and understand the methods and mechanisms and Computer aided drug design is applicable in Cancer disease, conveyance of drug to specific site in body, data collections and storages of organics and biological.

Relevant Conferences:

3rd International Conference on Medicinal Chemistry & Computer Aided Drug Designing18 - 20 August 2014, Beijing, China. 9th National  Symposium cum Workshop on “Recent Trends in Structural Bioinformatics and Computer Aided Drug Design” 14 Feb 2017 - 17 Feb 2017 Karaikudi, India.Computer Aided Drug Design, Next Generation Computer-Aided Medicine Design: Going Beyond Traditional Targets, Pathways, Modalities, Agents and Techniques,  July 16-21, 2017 Mount Snow West Dover, VT. 2nd International Conference on  Design and Production Engineering  August 21-22, 2017 Birmingham, UK.

Relevant Societies:

Computer Retrieval of Information on Scientific Projects (CRISP) (NIH)| Scientifc Computing Magazine| Pharmaceutical Society of Ireland| Association of the British Pharmaceutical Industry (ABPI).

Track 4: Biomarkers In Drug Discovery & Development

Biomarkers are fast becoming an essential part of clinical development, because they offer a faster alternative to the conventional drug development approach and also safe drugs in greater number .The global market of biomarkers was valued at USD 23.9 billion in 2015 and the global market of biomarkers is expected to reach $45.55 billion by 2020 from $23.9, and at a CAGR of 13.58% between 2015 and 2020. Increasing health care expenditure & R&D spending and the increasing utility of biomarkers for diagnostics are expected to drive the market. On the other hand, the need for high capital investment, low benefit-cost ratio, poorly suited regulatory & reimbursement systems, and the high cost of tests and sample collection &and storage are the major factors restraining the growth of this market.

Relevant Conferences:

9th International Conference and Expo on Molecular & Cancer Biomarkers August 24-25, 2017 Birmingham, UK. 10th International Conference on Biomarkers & Clinical Research Oct 16-18, 2017 Chicago, USA. 9th Internationl Conference on Biomarkers August 07-09, 2017 Osaka , Japan.  Biomarker  Summit  2017, on March 20-22, 2017 in San Diego. 7th  International  Conference  and Expo on Molecular & Cancer Biomarkers September 15-16, 2016 Berlin, Germany. 12th  Annual  Biomarkers  Congress  21-22 February 2017, Manchester, UK.  Diagnostics World Congress 02-04 May 2017 Philadelphia   Marriott Downtown, PhiladelphiaUSA. Biomarkers for Cancer Immunotherapy February 23-24, 2017,San Francisco, CA.  2nd Annual Biomarker Conference on  6-7 of February 2017,  San Diego-CA, USA.

Relevant Societies:

International society of oncology and biomarkers  |The Biomarkers Consortium| National Cancer Institute Center for Cancer Research (NCI).

Track 5: Immunotherapy

In the last few decades immunotherapy has become an important part of treating various diseases particularly in treating some types of cancer. Newer types of immune treatments are now being studied. In 2015, the global cancer immunotherapy market was valued at USD $37.50 billion, with its revenue expected to progress at a very strong CAGR of 14.6% with in a forecast period from 2016 to 2024, and the global cancer immunotherapy market is expected to reach USD $124.88 billion by the end of 2024. The Europe cancer immunotherapy market was worth $ 13.20 billion in 2016 and is estimated to reach $ 23.41 billion by the end of 2021 with growing potential of 12.45%.

Relevant Conferences:

13th Annual Biomarkers &  Immuno - oncology World Congress 2017, May 2-4, 2017 Philadelphia Downtown.  3rd Annual Engineering  Next-Generation  Cancer Immunotherapies, January 9-10, 2017 Hilton San Diego Bayfront. 15th World Cancer Convention  November 27-28, 2017  Dubai, UAE. 2nd  International Conference on Tumor & Cancer Immunology and Immunotherapy July 17-18, 2017 Chicago, Illinois, USA. 9th World Congress and Expo on Immunology November  2-3, 2017 Atlanta, Georgia, USA. 9th World Congress on Immunity,  Inflammation and Immunotherapies November 02-03, 2017 Atlanta, Georgia, USA. Cancer Immunotherapy February 20-22, 2017 San Francisco, CA. 19th International Conference  on  Tumor  Immunology and Immunotherapy London, United Kingdom, February 16 - 17, 2017.Immune Regulation in Autoimmunity and Cancer (D1), March 26-30, 2017,  British Columbia, Canada.Tumor Metabolism: Mechanisms and Targets (X3), March 5-9, 2017, British Columbia, Canada.

Relevant Societies:

American Association of Immunologists (AAI) | Alliance for Nanotechnology in Cancer(NCI) | National Cancer Institute Center for Cancer Research (NCI) | Society for Immunotherapy of Cancer (SITC) | International Society for Biological Therapy of Cancer.

Track 6: Antibody Research

Monoclonal antibodies have become important treatments for cancer, inflammation and a wide range of other diseases, representing an increasing share of the most successful pharmaceutical markets. Monoclonal antibodies (mAbs) are remarkably versatile protein molecules with numerous applications in human health. More than 30 mAb therapeutics have been approved for marketing and approximately 360 mAbs are currently in clinical studies, with 30 in pivotal trials. 

Relevant Conferences:

Antibody engineering &therapeutics, December 10-14, 2017Manchester Grand Hyatt San Diego,San Diego, CA. Americas Antibody Congress 2017,May 23-24, 2017   San Diego, CA, United States. Stem Cells as Discovery & Research Tools Forum 2017,January 17-21, 2017 Miami, United State. European Antibody Congress 2017,November 2017 ,  Geneve, Switzerland. 10th Annual Proteins & Antibodies Congress 24-25 April 2017, Novotel  London West, London, UK. 3rd Antibodies and Bio Therapeutics Congress November 08-09, 2017 Las Vegas, Nevada, USA.

Relevant Societies:

Antibody Society | British Society for Histocompatibility and Immunogenetics| Antibody engineering and therapeutics |  American Association of Immunologists (AAI).

Track 7: Recent Advances in Spectroscopy

New mass spectrometry (MS) methods, collectively known as data autonomous analysis and hyper reaction monitoring, have recently developed. The analysis of peptides generated by photolytic breakdown of proteins, known as bottom-up proteomics, supports as the basis for many of the protein research undertaken by mass spectrometry (MS) workshops. Discovery-based or shotgun proteomics employs data-dependent acquisition (DDA). Herein, a hybrid mass spectrometer first performs a survey scan, from which the peptide ions with the intensity above a predefined threshold value, are stochastically selected, isolated and sequenced by product ion scanning. Targeted proteomics, selected environmental Monitoring (ERM), also known as multiple reactions monitoring (MRM), is used to monitor a number of selected precursor-fragment transitions of the targeted amino acids. The selection of the SRM transitions is normally calculated on the basis of the data acquired previously by product ion scanning, repository data in the public databases or based on a series of empirical rules predicting the Enzyme structure sites.

Relevant Conferences:

7th European Biosimilars Congress May 15-17, 2017  Munich, Germany; 8th World Congress on Pharmacology, August 07-09, 2017, Paris, France; 6th World Pharmacists and Clinical Pharmacy Annual Congress May 22-24, 2017 Chicago, USA; 8th Annual Pharmaceutical Analysis Congress September 25-27,2017 Vienna, Austria ; Drug Discovery and Therapy World Congress July 10-13, 2017, USA; 4th Annual Drug Discovery Congress October 2017, USA; 18th Annual Drug Discovery Summit 12-13 June 2017, Berlin, Germany; 3rd Drug Discovery Re-Invented Conference  February 21-24 2017 Cancun, Mexico.

Relevant Societies:

Society for Applied Spectroscopy | American Society for Mass Spectrometry|  Federation of Analytical Chemistry and Spectroscopy Societies (FACSS) | Indian Society for Mass Spectrometry (ISMAS)| Spectroscopy Society of Pittsburgh

Track 8: Proteomics Drug Discovery

Proteins are the major targets of drug discovery. Most large pharmaceutical companies now have a proteomics-oriented biotech or academic companion or have started their own proteomics division. Common applications of proteomics in the drug manufacturing include target identification and validation, identification of efficacy and toxicity biomarkers from readily accessible biological fluids, and studies into mechanisms of drug action or toxicity. Target identification and validation involves identifying proteins whose expression levels or activities change in disease states. These proteins may help as potential therapeutic targets or may be used to classify patients for clinical trials. Proteomics technologies may also support identify protein-protein interactions that influence either the disease state or the proposed therapy. Efficiency biomarkers are used to assess whether target modulation has occurred.

Relevant Conferences:

7th European Biosimilars Congress May 15-17, 2017  Munich, Germany; 8th World Congress on Pharmacology, August 07-09, 2017, Paris, France; 6th World Pharmacists and Clinical Pharmacy Annual Congress May 22-24, 2017 Chicago, USA; 8th Annual Pharmaceutical Analysis Congress September 25-27,2017 Vienna, Austria ; Drug Discovery and Therapy World Congress July 10-13, 2017, USA; 4th Annual Drug Discovery Congress October 2017, USA; 18th Annual Drug Discovery Summit 12-13 June 2017, Berlin, Germany; 3rd Drug Discovery Re-Invented Conference  February 21-24 2017 Cancun, Mexico.

Relevant Societies:

British Society for Proteome Research | Australasian Proteomics Society| The Protein Information Resource PIR (NBRF) |The Protein Society.

Track 9: Pharmaceutical Research & Development

In discovery process includes the early phases of research, which are designed to identify an investigational drug and perform primary tests in the lab. This first stage of the process takes approximately three to six years. By the end, researchers hope to identify a promising drug aspirant to further study in the lab and in animal models, and then in people.

These advances offer great promise, but also add complexity to the R&D process. In order to ensure the safety and efficacy of personalized therapies that are used alongside diagnostics, clinical trial protocols must be modified and enhanced. This may need the use of additional procedures and resources, as well as new or innovative forms of data collection. Moreover, by their very nature, the patient population identified to respond to targeted therapies is narrower, which makes patient recruitment more difficult.

Relevant Conferences:

7th European Biosimilars Congress May 15-17, 2017  Munich, Germany; 8th World Congress on Pharmacology, August 07-09, 2017, Paris, France; 6th World Pharmacists and Clinical Pharmacy Annual Congress May 22-24, 2017 Chicago, USA; 8th Annual Pharmaceutical Analysis Congress September 25-27,2017 Vienna, Austria ; Drug Discovery and Therapy World Congress July 10-13, 2017, USA; 4th Annual Drug Discovery Congress October 2017, USA; 18th Annual Drug Discovery Summit 12-13 June 2017, Berlin, Germany; 3rd Drug Discovery Re-Invented Conference  February 21-24 2017 Cancun, Mexico.

Relevant Societies:

European Pharmaceutical Union (EPU)|Pharmaceutical Group of the European Union (PGEU)| American Association of Pharmaceutical Scientists (AAPS)|Association of the British Pharmaceutical Industry (ABPI).

Track 10: Computational Chemistry

In pharmaceutical industry, a major employer of computational chemists, has historically focused on the discovery and design of new small-molecular therapeutics. Recently, but, there is a trend to apply computational chemistry and cheminformatics (a field that syndicates laboratory data, chemical modeling, and information science methods) to process development, analytical chemistry, and biologics (medicinal products manufactured using or extracted from biological sources). Computational chemists use mathematical algorithms, statistics, and large databases to integrate chemical theory and modeling with trial observations. Some computational chemists create models and simulations of physical processes, and others use statistics and data analysis procedures to extract useful information from large bodies of data. Advances in computer visualization abilities make it possible for the computational chemist to present complex analyses in a readily logical form, which they can use to design trials and new materials and validate the results.

Relevant Conferences:

11th Triennial Congress of the World Association of Theoretical and Computational Chemists, 27 Aug - 01 Sep 2017 Munich, Germany.  6th World conference on  Physico-Chemical Methods in Drug Discovery and Development 04 Sep 2017 - 06 Sep 2017,Zagreb, Croatia. Computational Molecular Science 2017,19-22 March 2017,  UK. Virtual Winter school on Computational Chemistry,18-20 January 2017,UK. 3rd International Conference and Exhibition on Advances in  Chromatography & HPLC Techniques July 13-14, 2017 Berlin, Germany. 6th World Congress on Medicinal  Chemistry and Drug Design June 7-8, 2017 Milan, Italy. 2nd International  Conference on Applied Chemistry October 16-17, 2017 Toronto, Canada.  2nd International  Conference and Exhibition on Polymer Chemistry November 06-08, 2017 Chicago, USA. 10th Annual  Chemistry Congress October 18-19, 2017 Osaka, Japan.

Relevant Societies:

Royal Society of Chemistry| Society of Chemical Industry| Hungarian Chemical Society| European Association for Chemical and Molecular Sciences| Belgian Society of Biochemistry and Molecular Biology.

Track 11: Advanced Trends In Medicinal Chemistry In Drug Discovery And Designing

Today new biological targets, methodologies and advanced computing have improved modern drug discovery and have given medicinal chemistry a more profound skill set and toolkit to grasp the nuances  of disease pathophysiology. The medicinal chemistry related approaches and methodologies in drug discovery increases the productivity in drug discovery and decrease attrition. Mainly in drug designing structure-based drug design, fragment –based drug design, natural product-based drug design, diversity-based drug design, and chemo genomics are applied.

Relevant Conferences:

2nd International Conference  on Pharmaceutical Chemistry  October 02-04, 2017 Barcelona, Spain. 4th European Chemistry  Congress  May 11-13, 2017 Barcelona, Spain.  2nd International Conference and Exhibition on Materials Chemistry  July 13-14, 2017 Berlin,  Germany. 3rd International  Conference  on Electrochemistry July 10-11,2017 Berlin, Germany 4th World Congress  on Chromatography August 07-09, 2017 Rome, Italy. 6th World Congress on Medicinal Chemistry  and Drug Design June 7-8, 2017 Milan, Italy.  26th International Society  of Heterocyclic Chemistry Congress 03 - 08 September 2017, Regensburg (DE).  Blue Danube Symposium on Heterocyclic Chemistry  2017  August - 02 September 2017, Linz (AT). 18th Tetrahedron Symposium - Asia Edition 23 - 27 July 2017, Melbourne (AU). 18th Tetrahedron Symposium - New Developments in Organic Chemistry 27 - 30 June  2017, Budapest (HU).

Relevant Societies:

International Conference on Chemical Structure | International Council of Chemical Associations| European Federation for Medicinal Chemistry| The American Chemical Society (ACS)

Track 12: Insilco Drug Discovery

Insilco methods can help in classifying drug targets via bioinformatics tools. They can also be used to analyse the target structures for probable binding/ active sites, generate candidate molecules, check for their drug likeness, berth these molecules with the target, rank them according to their binding affinities, further optimize the molecules to improve binding appearances. The use of computers and computational methods permeates all aspects of drug discovery today and forms the core of structure-based drug design. High-performance computing, data management software and internet are facilitating the access of huge amount of data generated and transforming the massive complex biological data into effective knowledge in modern day drug discovery process. The use of complementary experimental and informatics techniques increases the chance of success in many phases of the discovery process, from the identification of novel targets and elucidation of their functions to the discovery and development of lead compounds with desired properties. Computational tools offer the improvement of delivering new drug candidates more quickly and at a lower cost. Major roles of computation in drug discovery are; (1) Effective screening & de novo design, (2) in silico ADME/T prediction and (3) Advanced techniques for determining protein-ligand binding.

Relevant Conferences:

7th European Biosimilars Congress May 15-17, 2017  Munich, Germany; 8th World Congress on Pharmacology, August 07-09, 2017, Paris, France; 6th World Pharmacists and Clinical Pharmacy Annual Congress May 22-24, 2017 Chicago, USA; 8th Annual Pharmaceutical Analysis Congress September 25-27,2017 Vienna, Austria ; Drug Discovery and Therapy World Congress July 10-13, 2017, USA; 4th Annual Drug Discovery Congress October 2017, USA; 18th Annual Drug Discovery Summit 12-13 June 2017, Berlin, Germany; 3rd Drug Discovery Re-Invented Conference  February 21-24 2017 Cancun, Mexico.

Relevant Societies:

Insilico Medicine|  In Silico Medicinal Chemistry |Directory of in silico Drug Design tools.

Track 13: Innovative Drug Discovery And Nanotechnology

Nanotechnology has already begun to revolutionize medicine. Nanotechnology involves the use of materials with fundamental length scales in the nanometer dimension which demonstrate significantly changed properties compared to micron structured materials. Such materials can include particles, fibers, grain sizes, etc. This session highlighted the advancements nanotechnology is making in medicine in such fields as disease prevention, diagnosis, and treatment including (but not limited to) drug delivery, tissue engineering, implants, sensors, cancer treatment, and toxicity.

Relevant Conferences:

7th European Biosimilars Congress May 15-17, 2017  Munich, Germany; 8th World Congress on Pharmacology, August 07-09, 2017, Paris, France; 6th World Pharmacists and Clinical Pharmacy Annual Congress May 22-24, 2017 Chicago, USA; 8th Annual Pharmaceutical Analysis Congress September 25-27,2017 Vienna, Austria ; Drug Discovery and Therapy World Congress July 10-13, 2017, USA; 4th Annual Drug Discovery Congress October 2017, USA; 18th Annual Drug Discovery Summit 12-13 June 2017, Berlin, Germany; 3rd Drug Discovery Re-Invented Conference  February 21-24 2017 Cancun, Mexico.

Relevant Societies:

Foresight Nanotech Institute |International Association of Nanotechnology (IANT)|IEEE Nanotechnology Council |Institute for Molecular Manufacturing (IMM) |Microscopy Society of America (MSA)|Nano Business Alliance |Nanotechnology and Nanoscience Student Association (NANSA).

Track 14: Novel Detection Technologies And Drug Discovery

The pharmaceutical sector, a cornerstone of the healthcare industry, is undergoing dramatic change, primarily caused by reduced output of new medicines from research and development (R&D) laboratories, drug pricing pressures, stricter regulatory environments and the overall current economic downturn. This makes demands of all pharmaceutical companies to find better ways to increase their output of new drugs, through innovation, to both treat patients and meet their shareholders’ expectations.

Relevant Conferences:

7th European Biosimilars Congress May 15-17, 2017  Munich, Germany; 8th World Congress on Pharmacology, August 07-09, 2017, Paris, France; 6th World Pharmacists and Clinical Pharmacy Annual Congress May 22-24, 2017 Chicago, USA; 8th Annual Pharmaceutical Analysis Congress September 25-27,2017 Vienna, Austria ; Drug Discovery and Therapy World Congress July 10-13, 2017, USA; 4th Annual Drug Discovery Congress October 2017, USA; 18th Annual Drug Discovery Summit 12-13 June 2017, Berlin, Germany; 3rd Drug Discovery Re-Invented Conference  February 21-24 2017 Cancun, Mexico.  

Relevant Societies:

Biochemical Society |American Chemical Society |American Society of Human Genetics (ASHG) |Genetic Analysis Software (NIH).

Track 15: Novel Therapeutic Approaches In Treating Ocular Diseases

There is an impelling need to develop effective therapeutic strategies for patients with retinal disorders. From the past two decades on the mechanisms governing degeneration of the retina, it is now possible to devise innovative therapies based on retinal gene transfer. In gene transfer method we can correct the specific genetic defect in inherited retinal diseases, strategies to delay the onset of blindness independently of the disease-causing mutations and strategies to reactivate residual cells at late stages of the diseases. Under gene specific strategies like gene replacement for recessive inherited retinal disorder, gene-specific therapy for dominant inherited retinal disorders. Under non gene-specific therapies for ocular diseases mainly gene therapies modulating the secondary mechanisms of retinopathies, and  optogenetics.

Relevant Conferences:

International Conference on Eye and Vision August 21-23, 2017 Toronto, Canada.  World Congress and  Expo on Optometry  and  Vision Science  July 17-19, 2017 Chicago, USA. 17th Global Ophthalmology  and  Glaucoma Conference November 27-28, 2017 Dubai, UAE. 2nd Global Pediatric  Ophthalmology  Congress June 05-06, 2017 Milan, Italy.9th Global Ophthalmology Summit March 15 - 16, 2017 London, UK. 9th Ocular Diseases Drug Discovery Conference  on March 20-21, 2017 in San Diego, CA.  3rdAsia - Australia Congress on Controversies in Ophthalmology 09 - 12  2017,Seoul, South Korea.  9th Ocular Diseases Drug Discovery Conference  20–21 March 2017 San Diego, United States. Current Concepts in Ophthalmology 2017, January 6- 7, 2017, Caesars Atlantic City.  European Eye Bank Association 28th Annual Meeting 2017  January 22- 23, 2017 Prague .

Relevant Societies:

American Academy of Ophthalmology |International Council of Ophthalmology| European Society of Ophthalmology |Malaysian Society of Ophthalmology (MSO) |Georgia Society of Ophthalmology.

About Conference

Conference Series is delighted to invite you to attend the 3rd International Conference and Expo on Drug Discovery & Designing, one of its remarkable Pharmaceutical conferences, to be held during October 02-04, 2017 in Vienna, Austria emphasizing on recent areas of more optimized research techniques like rational and computer aided drug designing for the Discovery, Designing and Development of new drugs than by traditional hit and trial method. To know more about Conference series.

Drug Discovery conferences-2017 focuses on discussing the treatment strategies, risk management and consequences and challenges in drug design and discovery industry. Drug Discovery conferences-2017 provides a platform to critically analyse and understand the methods and mechanisms.

Why to attend???

The Drug Discovery 2017 anticipates participants, renowned speakers and eminent delegates across the globe to be attending the conference to share their valuable presentation and galvanize the scientific community. Scientific people from all over the globe focused on learning about emerging technologies about Drug Discovery and Designing. This is a best globalised opportunity to reach the largest assemblage of participants from the scientific community and research.

Target Audience:

  • Noble laureates
  • Pharmaceutical Researchers
  • Pharmaceutical Industry Professionals (CEOs, MDs, Directors)
  • Academicians (Professors, Deans, Directors,)
  • Pharmaceutical Associations and Societies
  • Young Researchers and Students
  • Post- Doctorals

 

Market Analysis

Drug Design is an impressive inventive process of new medication on the basis of biological target. Drug Discovery Informatics Market size was USD 1.6 billion in 2015 and is anticipated to reach around USD 6.5 billion by 2023.
 
This graph showing the Drug Discovery Informatics Market in U.S in million dollars. In 2012 total market for Drug Discovery Informatics was around in between 400 to 500 million, and is expected to reach around more than 3,500 million in 2022. Drug discovery is a complex process and represents a main component of the pharmaceutical industry. According to a new technical market research report, the global market for drug discovery technologies and products was worth $38.4 billion in 2011. This figure is projected to reach $41.4 billion in 2012 and $79 billion in 2017, a five-year compound annual growth rate (CAGR) of 13.8%.The following graph showing global market for Drug Discovery technologies and products in billion between 2011 to 2017.
Fig 3

The fundamental goal is to predict whether a given molecule will bind to a target and if so how strongly. The biosimulation market is expected to reach USD 2,107.99 Million by 2020 from USD 1,034.93 Million in 2015, growing at a CAGR of 15.29% between 2015 and 2020. A strong trend of R&D investments in biotechnology and pharmaceutical industries will majorly drive the biosimulation market. The global market of biomarkers was valued at USD 23.9 billion in 2015 and the global market of biomarkers is expected to reach $45.55 billion by 2020 from $23.9, and at a CAGR of 13.58% between 2015 and 2020.

U.S. biomarkers market, by disease, 2013 - 2024 (USD Million)

Fig 3

The above graphical representation shows the Biomarkers market, by disease  in U.S in Million. It represents that the overall market for Biomarkers in 2013 was in between 5,000 to 10,000 USD Million and is expected to reach range of 30,000 to 35,000 by 2024. In 2015, the global cancer immunotherapy market was valued at USD $37.50 billion, with its revenue expected to progress at a very strong CAGR of 14.6% with in a forecast period from 2016 to 2024, and the global cancer immunotherapy market is expected to reach USD $124.88 billion by the end of 2024. The Europe cancer immunotherapy market was worth $ 13.20 billion in 2016 and is estimated to reach $ 23.41 billion by the end of 2021 with growing potential of 12.45%. The global monoclonal antibodies (mAbs) market was valued at USD 85.4 billion in 2015 and is expected to reach a value of USD 138.6 billion by 2024, a growth rate of 5.7% over the forecast period.

 
Monoclonal Antibodies Market, By source Type, 2013 - 2024 (USD Billion)

Fig 3

The global mass spectrometry market for the forecast  period of 2015 to 2020. This market is expected to reach USD 7,279.1 Million by 2020 from USD 4,919.9 in 2015 at a CAGR of 8.1% during the forecast period. The global spectroscopy market reached $13.5 billion in 2015 and should reach $15.6 billion in 2020, a compound annual growth rate (CAGR) of 2.9% through 2020.The graph represents that "Near infrared emerged as the most widely used technology of process spectroscopy". The global proteomics market is projected to reach USD 21.87 Billion by 2021, at a CAGR of 11.7% from 2016 to 2021. The global proteomics market exhibits potential for significant growth and is propelled by the increasing need for personalized medicine, R&D expenditure, technological advancements, and increased funding for proteomics projects. Pharmaceuticals represented a US$300 billion-a-year market globally as of 2015, the World Health Organization states. The global pharmaceutical market is expected to surpass US$400 billion by 2018.

Fig 3

The global market for computational medicine and drug discovery software was estimated to be $5.2 billion in 2015 and is projected to escalate to $7.1 billion by 2021.

Fig 3

The global market for nanoparticles in the life sciences is estimated at over $29.6 billion for 2014. This market is forecast to grow to more than $79.8 billion by 2019, to register a healthy compound annual growth rate (CAGR) of 22%. The biggest increase will come in the area of drug delivery systems.

Fig 3

 

 
The global ophthalmic drugs market was valued at US$16 bn in 2012 and is estimated to reach a market value of US$21.6 bn by 2018, rising at a CAGR of 5.2% from 2013 to 2018.
Fig 3

 

 

 

Past Conference Report

Drug Discovery 2016

 

We gratefully thank all our wonderful Speakers, Conference Attendees, Students, Media Partners, and Associations for making Drug Discovery 2016 Conference the best ever!

The 2nd International Conference and Expo on Drug Discovery & Designing, hosted by the Conference Series LLC was held during October 27-29, 2016 at Rome, Italy, based on the theme “Biological Targets for Advances in Drug Discovery and Logical Design of Therapeutic Agents ". Benevolent response and active participation was received from the Organizing Committee Members along with Scientists, Researchers, Students and leaders from various fields of Pharmaceutical sciences and Drug Discovery, who made this event a grand success.

Conference Series LLC expresses its gratitude to the conference Moderator, namely Dr. Chang -Guo Zhan for taking up the responsibility to coordinate during the sessions. We are indebted to your support.

The conference was initiated with the Honourable presence of the Keynote forum. The list includes:

The meeting reflected various sessions, in which discussions were held on the following major scientific tracks:

•   Perspective in Drug Discovery

•    Biomarkers in Drug Designing

•    Ligand Based Drug Discovery

•    Scaffold Based Drug Discovery

•    Drug Discovery Software’s

•    CNS Drug Discovery

•    GPCRs Drug Discovery

•    Insilico Drug Discovery

•    Chemoinformatics Drug Discovery

•    Proteomics Drug Discovery

•    Computational Chemistry

•    Computer Aided Drug Designing (CADD)

•    fragment Based Drug Discovery

•    Antibiotics Drug Discovery

•    Mass Spectrometry Drug Discovery

•    Drug Designing

•    structured Based Drug Design

•    Screening and Drug Design

•    Drug Delivery Using Nanotechnology

•    Cardiovascular Drug Discovery

•    Biologics

•    Pharmaceutical Research & Development

•    Entrepreneurs Investment Meet

Conference series LLC thank all our expert presenters from all around the world which includes various outside experts, University representatives and other eminent researchers who supported the conference by facilitating the discussion forums.

With the grand success of Drug Discovery-2016, Conference Series LLC take the immense pleasure to announce the “3rd International Conference and Expo on Drug Discovery & Designing "to be held during October 02-04, 2017 at Vienna, Austria.

For More details visit: http://drug-discovery.pharmaceuticalconferences.com

 

 

                                                        


Past Reports  Proceedings  Gallery  

Supported By

Drug Designing Journal of Developing Drugs Journal of Pharmaceutical Sciences & Emerging Drugs

All accepted abstracts will be published in respective Conferenceseries International Journals.

Abstracts will be provided with Digital Object Identifier by


Media partners & Collaborators & Sponsors

mediapartner

Media Partner

mediapartner

Media Partner

mediapartner

Media Partner

Past Affiliations

Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos
Speaker Logos